Complement C5 mAb in the Treatment of Anti-GBM Disease

Summary

Anti-GBM disease is the most severe form of glomerulonephritis. Despite of the standard treatment including plasmapheresis and immunosuppressant, 70% of the patients still go into end-stage kidney disease. Complement has been shown to participate in the pathogenesis of anti-GBM disease. This study aims to the investigate the therapeutic effects and safety of C5 monoclonal antibody in the treatment of anti-GBM disease.

Timeline

Start

2024-03-01

Primary completion

2025-11-03

Completion

2025-11-03

Drugs

Indications